The United States Food and Drug Administration has tentatively approved the first generic version of a twice-yearly injection to prevent HIV, a decision announced on Monday, November 2, 2026, that could bring a breakthrough prevention drug within reach of millions of people in low- and middle-income countries at an expected cost of $40 per person per year.
The generic version of lenacapavir was developed by India-based Dr. Reddy’s Laboratories, and the tentative approval was announced by the company and by Unitaid, a global health initiative that helped accelerate the drug’s development. The drug is expected to be available in 120 low- and middle-income countries, at a price comparable to daily HIV prevention pills, according to Unitaid and reporting by the Associated Press.
What tentative approval means
Tentative approval is the FDA’s standard designation for a generic drug while the original product remains under patent, according to Unitaid and FDA reporting. It does not permit the generic to be sold in the United States, but it confirms that the product has met the FDA’s quality and safety standards and makes it eligible for purchase by the US government for use abroad. Approval by the US FDA can also speed up regulatory approval in many other countries, according to the Associated Press.
That distinction matters for understanding the announcement. The generic will not be available in American pharmacies, where the brand-name version, marketed by Gilead Sciences as Yeztugo, carries a list price of $28,218 per year before insurance, according to reports. In the 120 countries covered by Gilead’s voluntary licensing programme, however, the generic is expected to cost $40 per person per year — a difference that health organisations say could transform access.
Lenacapavir was first developed by Gilead Sciences and was approved by the FDA in June 2025 after large clinical trials showed it to be highly effective at preventing HIV, according to reports. It is the world’s only twice-yearly injection for HIV prevention, which means people need only two doses a year instead of a daily pill. Health experts have long argued that less frequent dosing could help people who struggle to take a pill every day, including people in settings where daily medication is difficult to sustain.
How the $40 price was reached
The $40 price comes from a pricing agreement announced in September 2025 between Unitaid, the African health research institute Wits RHI, the Clinton Health Access Initiative and Dr. Reddy’s Laboratories, according to Unitaid. The agreement paired an early pricing commitment with financial, technical and regulatory support to speed up the generic’s development.
The path to a generic began in October 2024, when Gilead granted royalty-free voluntary licences to six generic manufacturers — Dr. Reddy’s, Emcure, Eva Pharma, Ferozsons, Hetero and Mylan — according to reports. Those licences permit generic production and supply across the 120 designated countries, while Gilead retains patent protection in markets outside the licensing arrangements. Dr. Reddy’s is the first of those manufacturers to receive FDA tentative approval; generic versions made by the other manufacturers have yet to be approved, according to the Associated Press.
Unitaid said the speed of the process was unusual. The tentative approval came just 16 months after the FDA approved Gilead’s original product in June 2025, according to Unitaid, whereas generic versions of new drugs often take many years to reach low-income markets. “Getting a generic approved just 16 months after the originator, rather than a decade later, shows what is possible when we prioritise access from the start,” Unitaid said in its announcement, according to reports.
Why access has been a problem until now
Until now, Gilead has been the sole supplier of lenacapavir, and demand has outstripped supply in low- and middle-income countries, according to the Associated Press. Even before generic availability, more than 125,000 people in ten early-adopter African countries had already started Gilead’s lenacapavir, Unitaid said, but that figure is small compared with the number of people who could benefit.
HIV has killed more than 40 million people over four decades, according to reports, and prevention remains a central part of the global response alongside treatment. Daily prevention pills, known as PrEP, are effective but require consistent daily use, and adherence can be difficult. A twice-yearly injection removes that daily burden, but only if it is affordable and available where it is needed most.
The cost gap between the US list price and the generic price illustrates the access problem in stark terms. At more than $28,000 a year in the United States, the brand-name drug is out of reach for most health systems in low-income countries without subsidies or licensing deals. At $40 a year, health organisations say, the drug becomes comparable in cost to daily pills and therefore a realistic option for national programmes.
When will the generic actually reach people?
Initial generic supplies are expected to reach some countries by the end of 2026, according to Unitaid and reporting, although it could take longer in countries that require the drug to go through their own approval processes before people can start taking it. Broader availability is anticipated in 2027, according to reports.
That timeline means the tentative approval is a milestone rather than an immediate solution. National regulators in the 120 countries will still need to approve the product, supply chains will need to be established, and health workers will need training to deliver an injectable prevention drug at scale. But health organisations involved in the effort say the FDA decision removes one of the biggest obstacles, because many countries rely on FDA approval as a signal of quality when making their own decisions.
The approval also matters for the US government’s own purchasing. Because tentative approval makes the product eligible for purchase by the US government, it opens the door to US-funded programmes supplying the generic abroad, according to reports. That could help bridge the gap between the first supplies at the end of 2026 and wider rollout in 2027.
What happens next
The next steps will be watched closely by global health organisations. First, whether other generic manufacturers in the voluntary licensing programme also receive FDA tentative approval, which would increase supply and competition. Second, how quickly national regulators in the 120 countries approve the generic and how fast supplies can be scaled up. Third, whether the $40 price holds as production expands, and whether funding for prevention programmes keeps pace with the new option.
For now, the announcement has been welcomed as a significant step. Health organisations say it brings the world closer to making a twice-yearly HIV prevention shot available to millions more people for $40 a year — a price that, for the first time, puts this form of prevention within realistic reach of the countries where HIV burden remains highest.
The drug does not replace other prevention methods, and health experts stress that testing, treatment and other prevention tools remain essential. But for people who struggle with daily pills, and for health systems looking for simpler ways to deliver prevention, a twice-yearly injection at $40 a year represents a new option that was, until this week, largely theoretical outside a small number of early-adopter countries.
Sources: Associated Press; Unitaid announcement, November 2, 2026; MedicalXpress; The Hindu.
